Stock Events

Stock Events

Genelux 

$2.52
10
-$0.03-1.18% Thursday 20:00
+$0.05+1.98%Thursday 20:50After hours

Statistics

Day High
2.58
Day Low
2.46
52W High
8.54
52W Low
2.29
Volume
509,440
Avg. Volume
246,679
Mkt Cap
114.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.24
-0.23
-0.21
-0.19
Expected EPS
-0.194
Actual EPS
N/A

Financials

-401,812.5%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
8,000Revenue
-32.15MNet Income

Analyst Ratings

20.00Average Price Target
The highest estimate is 20.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GNLX. It's not an investment recommendation.
Apple
4
AAPL
Microsoft
4
MSFT
Tesla
4
TSLA
NVIDIA
4
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company that develops innovative therapeutics, including in oncology, which competes with Genelux's focus on cancer treatment.
Merck
MRK
Mkt Cap366B
Merck is a global healthcare company that produces cancer drugs and vaccines, directly competing with Genelux's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, competing in the same therapeutic area as Genelux.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a pharmaceutical corporation with a broad portfolio that includes oncology products, competing with Genelux's cancer-focused therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including oncology, competing with Genelux's cancer treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, making it a competitor to Genelux.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leader in oncology drugs and personalized medicine, directly competing with Genelux's approach to cancer treatment.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with Genelux.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing and commercializing medicines for serious medical conditions, including oncology, competing with Genelux.

About

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Show more...
CEO
Thomas D. Zindrick
Employees
26
Country
United States
ISIN
US36870H1032

Listings

BOATS
BOATS
GNLX.BOATS
XNAS
US
GNLX

0 Comments

Share your thoughts

FAQ

What is Genelux stock price today?▼
The current price of GNLX is $2.52 USD — it has decreased by -1.18% in the past 24 hours. Watch Genelux stock price performance more closely on the chart.
What is Genelux stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Genelux stocks are traded under the ticker GNLX.
Is Genelux stock price growing?▼
GNLX stock has fallen by -5.26% compared to the previous week, the month change is a -10.64% fall, over the last year Genelux has showed a -27.59% decrease.
What is Genelux market cap?▼
Today Genelux has the market capitalization of 114.02M
When is the next Genelux earnings date?▼
Genelux is going to release the next earnings report on November 18, 2026.
What were Genelux earnings last quarter?▼
GNLX earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.2 USD resulting in a -6.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Genelux revenue for the last year?▼
Genelux revenue for the last year amounts to 8,000 USD.
What is Genelux net income for the last year?▼
GNLX net income for the last year is -32.15M USD.
How many employees does Genelux have?▼
As of September 04, 2026, the company has 26 employees.
In which sector is Genelux located?▼
Genelux operates in the Health & Wellness sector.
When did Genelux complete a stock split?▼
Genelux has not had any recent stock splits.
Where is Genelux headquartered?▼
Genelux is headquartered in WESTLAKE VILLAGE, United States.